Nanexa AB (publ) (NANEXA) Licenses PharmaShell to Novo for Up to €1.165B
Nanexa granted Novo a global exclusive license to its PharmaShell platform for up to five peptide programs, with payments up to €1.165B including €615M in upfront and development/regulatory milestones, plus low single-digit royalties.Material DetailsContext by AI AnalystThis is a step-up validation…